Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome.

Autor: Abman SH; Department of Pediatrics, University of Colorado Anschutz School of Medicine and Children's Hospital Colorado, Aurora, CO, USA., Fox NR; Piedmont Athens Regional, Athens Pulmonary, Athens, GA, USA., Malik MI; Piedmont Athens Regional, Athens Pulmonary, Athens, GA, USA., Kelkar SS; OPEN Health, Bethesda, MD, USA., Corman SL; OPEN Health, Bethesda, MD, USA., Rege S; OPEN Health, Bethesda, MD, USA., Bhaloo J; OPEN Health, Bethesda, MD, USA., Shah R; OPEN Health, Bethesda, MD, USA., Shei RJ; Mallinckrodt Pharmaceuticals, Hampton, NJ, USA., Saporito D; Mallinckrodt Pharmaceuticals, Hampton, NJ, USA., Shamseddine N; Mallinckrodt Pharmaceuticals, Hampton, NJ, USA., DeBoer E; Mallinckrodt Pharmaceuticals, Hampton, NJ, USA., Wan GJ; Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.
Jazyk: angličtina
Zdroj: Drugs in context [Drugs Context] 2022 Apr 11; Vol. 11. Date of Electronic Publication: 2022 Apr 11 (Print Publication: 2022).
DOI: 10.7573/dic.2022-1-4
Abstrakt: Background: Inhaled nitric oxide (iNO) has been studied in patients with severe acute respiratory distress syndrome (ARDS) due to COVID-19 when it may be too late to impact disease course. This article aims to describe real-world iNO use and outcomes in patients with COVID-19 with mild-to-moderate ARDS in the United States.
Methods: This was a retrospective medical chart review study that included patients who were ≥18 years old, hospitalized for COVID-19, met the Berlin ARDS definition, received iNO for ≥24 hours continuously during hospitalization, and had a partial pressure of oxygen (PaO 2 )/fraction of inspired oxygen (FiO 2 ) ratio (P/F ratio) of >100 to ≤300 mmHg at iNO initiation. Outcomes included oxygenation parameters, physician-rated Clinical Global Impression-Improvement (CGI-I) scale scores, and adverse events. Response to iNO was defined as >20% improvement in P/F ratio.
Results: Thirty-seven patients at six sites were included. A P/F ratio of ≤100 was the most common reason for exclusion ( n =146; 83% of excluded patients). The mean P/F ratio (SD) increased from 136.7 (34.4) at baseline to 140.3 (53.2) at 48 hours and 151.8 (50.0) at 72 hours after iNO initiation. The response rate was 62% ( n =23). During hospitalization, no patient experienced adverse events, including methemoglobinaemia, airway injury, or worsening pulmonary oedema associated with iNO. At discharge, 54.0% ( n =20) of patients improved or remained stable according to the CGI-I.
Conclusion: In patients hospitalized with COVID-19 and mild-to-moderate ARDS, iNO was associated with improvement in the P/F ratio with no reported toxicity. This study provides additional evidence supporting a favourable benefit-risk profile for iNO in the treatment of mild-to-moderate ARDS in patients with COVID-19 infection.
Competing Interests: Disclosure and potential conflicts of interest: SSK, SLC, SR, JB and RS were employees of OPEN Health during the course of the study. OPEN Health received consulting fees from Mallinckrodt Pharmaceuticals, which funded the study. R-JS, DS, NS, ED, and GJW were employees of Mallinckrodt Pharmaceuticals while the study was being conducted. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/03/dic.2022-1-4-COI.pdf
(Copyright © 2022 Abman SH, Fox NR, Malik MI, Kelkar SS, Corman SL, Rege S, Bhaloo J, Shah R, Shei R-J, Saporito D, Shamseddine N, DeBoer E, Wan GJ, on behalf of the NOTICE Study Investigators.)
Databáze: MEDLINE
Externí odkaz: